Current manufacturer label
The four-day rule applies to one missed Zepbound dose
The current manufacturer DailyMed set for Zepbound is Eli Lilly tirzepatide injection labeling effective April 22, 2026. Its missed-dose section says to administer Zepbound as soon as possible within four days, or 96 hours, after a missed dose. If more than four days have passed, the missed dose is skipped and the next dose is administered on the regularly scheduled day. In either case, the regular once-weekly schedule then resumes. This is a calendar rule for a routine missed dose, not an instruction to calculate or add a catch-up amount.
- Count from when the injection was scheduled, not from when the missed dose was noticed or a reminder arrived.
- Confirm the last injection actually taken because an uncertain record is different from a confirmed missed dose.
- If the timing is close to the four-day boundary or cannot be reconstructed, ask the pharmacist or prescriber rather than estimating.
Weekly-day changes
A schedule change has a separate 72-hour spacing rule
The Zepbound label says the weekly administration day may be changed when necessary as long as at least three days, or 72 hours, separate two doses. The patient instructions also say not to take two Zepbound doses within 72 hours of each other. This spacing rule is not permission to add a dose, shorten a clinician-directed plan, alternate weekdays repeatedly, or use two injections to return to a preferred day.
- Use exact calendar dates and times; “earlier this week” does not establish a safe interval.
- Do not take two injections close together to make up for the missed injection or repair a reminder schedule.
- Ask who should document a new recurring weekday in the medication record, pharmacy directions, refill reminders, and follow-up plan.
Product and presentation identity
Zepbound instructions are not universal tirzepatide instructions
The current Zepbound label covers several branded presentations, including single-dose pens, single-dose vials, multi-dose vials, and single-patient-use KwikPens. Presentation-specific training still matters even though the label uses the same four-day missed-dose window. Mounjaro also contains tirzepatide but has a different brand and labeled use. A patient-specific compounded tirzepatide preparation is not FDA-approved Zepbound, is not a generic Zepbound equivalent, and must be checked against its own prescription and dispensing-pharmacy label.
- Read the brand, active ingredient, presentation, strength, device or vial, pharmacy, prescription date, and current directions before using a timing rule.
- If the Zepbound presentation changed, the manufacturer label says the patient or caregiver should receive training for the new presentation and consult its Instructions for Use.
- Do not transfer a Zepbound schedule to Mounjaro, compounded tirzepatide, semaglutide, retatrutide, or another product.
Long gaps and restarts
Multiple missed weeks require more than the routine four-day answer
The label’s four-day instruction answers a routine single missed-dose question; it does not provide one universal restart plan after several missed weekly injections or a prolonged interruption. Tolerability, current symptoms, prior strength, the reason for the gap, medication access, and any change in presentation or health status can affect the clinician’s decision. Do not restart, reduce, increase, split, stretch, or combine injections independently.
- Contact the care team when more than one weekly injection was missed, the interruption length is unclear, or the next package differs from the prior prescription.
- Explain whether the gap involved nausea, vomiting, diarrhea, constipation, low intake, dehydration, abdominal pain, illness, a procedure, pregnancy, storage, travel, or access problems.
- Do not use expired medication, a damaged or warm package, an unlabeled vial, another person’s medicine, or a research-use product to fill a calendar gap.
Symptoms and glucose medicines
A missed injection does not justify changing other medicines alone
A late or skipped Zepbound injection can overlap with gastrointestinal symptoms, reduced food or fluid intake, illness, diabetes, insulin, sulfonylureas, or another glucose-lowering medicine. The Zepbound label warns that hypoglycemia risk is higher with insulin or an insulin secretagogue and includes dehydration-related kidney, pancreatitis, gallbladder, severe gastrointestinal, hypersensitivity, and pregnancy precautions. A missed dose should not be used to invent a catch-up injection or independently change another medicine.
- Share the missed injection, current symptoms, food and fluid intake, glucose or CGM pattern when relevant, and every medicine with the responsible clinician.
- Do not stop, add, reduce, or increase insulin, a sulfonylurea, another GLP-1 medicine, or any prescribed treatment solely because Zepbound was late or skipped.
- Use urgent or emergency care for severe or persistent abdominal pain, repeated vomiting with inability to keep fluids down, severe low-glucose symptoms, fainting, confusion, trouble breathing, facial or throat swelling, or another emergency pattern.
Double-dose and access safeguards
Uncertain or excessive dosing needs prompt, product-specific help
If two doses may have been taken too close together, the amount is uncertain, or too much Zepbound may have been administered, do not wait for a routine refill or insurance response. The manufacturer patient instructions direct patients who take too much Zepbound to call their healthcare provider or Poison Help at 1-800-222-1222, or go to the nearest emergency room. A legitimate telehealth and pharmacy pathway should identify the exact product, prescriber, dispensing pharmacy, storage instructions, refill status, and urgent contact route.
- Keep the carton, device or vial, pharmacy label, lot information, dose record, and exact dates and times available when requesting help.
- Reject dose calculators, copied calendars, no-prescription checkout, research-use tirzepatide sold for treatment, hidden pharmacy sourcing, or compounded medication described as FDA-approved Zepbound.
- Peptide12 lists clinician-reviewed branded Zepbound and compounded tirzepatide pathways, but eligibility, a prescription, dispensing, coverage, and any schedule decision are not guaranteed.